In the clinical setting, it has been reported that lower expression of UCK1 is associated with blunted response to azacitidine[95] and that DCK is significantly reduced in the bone marrow and peripheral blood specimens from MDS patients who relapsed after decitabine[89], highlighting the importance of metabolic activation in the action of HMAs. The gene discussed is DCK; the disease is myelodysplastic syndrome.